TISIDB

Summary
Symbol	DEFA3
Name	defensin, alpha 3, neutrophil-specific
Aliases	HNP-3; HNP3; HP-3; defensin 3, neutrophil-specific; neutrophil peptide 3; Defensin, alpha 3; Neutrophil defe ......
Chromosomal Location	8p23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Secreted.
Domain	PF00323 Mammalian defensin PF00879 Defensin propeptide
Function	Defensin 2 and defensin 3 have antibiotic, fungicide and antiviral activities. Has antimicrobial activity against Gram-negative and Gram-positive bacteria. Defensins are thought to kill microbes by permeabilizing their plasma membrane.

> Gene Ontology [ TOP ]
Biological Process	GO:0001906 cell killing GO:0002227 innate immune response in mucosa GO:0002251 organ or tissue specific immune response GO:0002385 mucosal immune response GO:0006959 humoral immune response GO:0009615 response to virus GO:0009620 response to fungus GO:0009755 hormone-mediated signaling pathway GO:0019730 antimicrobial humoral response GO:0019731 antibacterial humoral response GO:0030518 intracellular steroid hormone receptor signaling pathway GO:0030520 intracellular estrogen receptor signaling pathway GO:0030522 intracellular receptor signaling pathway GO:0031640 killing of cells of other organism GO:0035821 modification of morphology or physiology of other organism GO:0042742 defense response to bacterium GO:0043401 steroid hormone mediated signaling pathway GO:0044364 disruption of cells of other organism GO:0048545 response to steroid hormone GO:0050830 defense response to Gram-positive bacterium GO:0050832 defense response to fungus GO:0051607 defense response to virus GO:0071383 cellular response to steroid hormone stimulus GO:0071396 cellular response to lipid GO:0071407 cellular response to organic cyclic compound GO:0098542 defense response to other organism
Molecular Function	-
Cellular Component	GO:0005766 primary lysosome GO:0005775 vacuolar lumen GO:0005796 Golgi lumen GO:0030141 secretory granule GO:0031983 vesicle lumen GO:0034774 secretory granule lumen GO:0035578 azurophil granule lumen GO:0042582 azurophil granule GO:0060205 cytoplasmic membrane-bounded vesicle lumen GO:0099503 secretory vesicle

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-1462054: Alpha-defensins R-HSA-6803157: Antimicrobial peptides R-HSA-1461973: Defensins R-HSA-168256: Immune System R-HSA-168249: Innate Immune System

Summary
Symbol	DEFA3
Name	defensin, alpha 3, neutrophil-specific
Aliases	HNP-3; HNP3; HP-3; defensin 3, neutrophil-specific; neutrophil peptide 3; Defensin, alpha 3; Neutrophil defe ......
Chromosomal Location	8p23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between DEFA3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	DEFA3
Name	defensin, alpha 3, neutrophil-specific
Aliases	HNP-3; HNP3; HP-3; defensin 3, neutrophil-specific; neutrophil peptide 3; Defensin, alpha 3; Neutrophil defe ......
Chromosomal Location	8p23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of DEFA3 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	DEFA3
Name	defensin, alpha 3, neutrophil-specific
Aliases	HNP-3; HNP3; HP-3; defensin 3, neutrophil-specific; neutrophil peptide 3; Defensin, alpha 3; Neutrophil defe ......
Chromosomal Location	8p23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of DEFA3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.124	0.488
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.303	0.576
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.004	0.992
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-2.185	0.0271
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-2.325	0.308
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-1.99	0.408
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0	1
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0	1
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0	1
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.443	0.358
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.942	0.651
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.244	0.367

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of DEFA3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	3.7	-3.7	0.415
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	7.7	-7.7	0.371
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	DEFA3
Name	defensin, alpha 3, neutrophil-specific
Aliases	HNP-3; HNP3; HP-3; defensin 3, neutrophil-specific; neutrophil peptide 3; Defensin, alpha 3; Neutrophil defe ......
Chromosomal Location	8p23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DEFA3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	DEFA3
Name	defensin, alpha 3, neutrophil-specific
Aliases	HNP-3; HNP3; HP-3; defensin 3, neutrophil-specific; neutrophil peptide 3; Defensin, alpha 3; Neutrophil defe ......
Chromosomal Location	8p23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DEFA3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DEFA3. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	DEFA3
Name	defensin, alpha 3, neutrophil-specific
Aliases	HNP-3; HNP3; HP-3; defensin 3, neutrophil-specific; neutrophil peptide 3; Defensin, alpha 3; Neutrophil defe ......
Chromosomal Location	8p23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DEFA3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	DEFA3
Name	defensin, alpha 3, neutrophil-specific
Aliases	HNP-3; HNP3; HP-3; defensin 3, neutrophil-specific; neutrophil peptide 3; Defensin, alpha 3; Neutrophil defe ......
Chromosomal Location	8p23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of DEFA3 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	DEFA3
Name	defensin, alpha 3, neutrophil-specific
Aliases	HNP-3; HNP3; HP-3; defensin 3, neutrophil-specific; neutrophil peptide 3; Defensin, alpha 3; Neutrophil defe ......
Chromosomal Location	8p23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between DEFA3 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	DEFA3
Name	defensin, alpha 3, neutrophil-specific
Aliases	HNP-3; HNP3; HP-3; defensin 3, neutrophil-specific; neutrophil peptide 3; Defensin, alpha 3; Neutrophil defe ......
Chromosomal Location	8p23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting DEFA3 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse DEFA3